Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
04:15pm, Thursday, 22'nd May 2025
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult pat
GSK's asthma drug Nucala wins FDA's approval to treat 'smoker's lung'
02:13pm, Thursday, 22'nd May 2025
The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic lung disease commonly known as "smoker's lung", the company said on Thursda
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 21'st May 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Gilead Sciences vs GSK: Which HIV Drugmaker is a Smarter Buy Now?
02:01pm, Tuesday, 20'th May 2025
Gilead Sciences, Inc. GILD and GSK GSK are pioneers in the human immunodeficiency virus (HIV) treatment space.
GSK or ACAD: Which Is the Better Value Stock Right Now?
12:41pm, Monday, 19'th May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attra
GSK's Blood-Cancer Treatment Combinations Approved in Japan
02:41am, Monday, 19'th May 2025
The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
08:55am, Thursday, 15'th May 2025
Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.
GSK splashes out $1.2bn up-front for liver treatment still in clinical trials
02:55am, Wednesday, 14'th May 2025
GSK PLC (LSE:GSK, NYSE:GSK) has struck a deal to acquire a drug to treat and prevent the progression of steatotic liver disease, poised for phase III clinical trials, for up to $2 billion. The disea
GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion
02:42am, Wednesday, 14'th May 2025
The pharma giant will pay $1.2 billion up-front for efimosfermin, with deal including potential success-based milestone payments of $800 million.
GSK to buy efimosfermin for up to $2 billion
02:24am, Wednesday, 14'th May 2025
British pharmaceutical giant GSK on Wednesday said it will buy efimosfermin, a phase III-ready potential specialty medicine from Boston Pharmaceuticals, for up to $2 billion.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Boston Pharmaceuticals, a leading clinical stage biopharmaceutical company developing highly targeted therapies for patients with serious
ITeos, GSK discontinue lung cancer therapy development
08:21am, Tuesday, 13'th May 2025
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival i
India's GlaxoSmithKline Pharma reports profit rise on strong demand
07:45am, Tuesday, 13'th May 2025
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.
Glaxo (GSK) Upgraded to Buy: Here's What You Should Know
01:05pm, Monday, 12'th May 2025
Glaxo (GSK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
